Glofitamab induces CR in patients with r/r DLBCL

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Data from the phase II NP30179 expansion study demonstrated that, after a median follow-up of more than 12 months, fixed-duration glofitamab—an investigational CD20xCD3 T cell-engaging bispecific antibody—induced durable complete responses in patients with relapsed or refractory diffuse large B-cell lymphoma who had received a median of three prior therapies.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login